Chronic News and Research

RSS

Campaign to educate customers on chronic pain management

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that it is launching a Direct Mail and Web campaign in an effort to educate customers on a recent report from the Center for Disease Control (CDC), stating that among all diabetics, 52% suffer from arthritis.

11 Sep 2009

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

Second-hand tobacco smoke exposure results in NAFLD

A team of scientists at the University of California, Riverside has found that even second-hand tobacco smoke exposure can result in nonalcoholic fatty liver disease (NAFLD), a common disease and rising cause of chronic liver injury in which fat accumulates in the liver of people who drink little or no alcohol.

11 Sep 2009

NCOA supports Obama for improving Medicare’s delivery system

NCOA applauds President Obama's call for universal health care. Older Americans with Medicare know first-hand the benefits of universal coverage -- and they should be in the forefront of efforts to secure the same rights for their children and grandchildren.

11 Sep 2009

KidneyTel system helps manage health issues faced by kidney patients

Kidney patients often have a number of serious chronic health issues in addition to their kidney disease. Fresenius Medical Care, the world’s leading renal therapies company, has developed the KidneyTel system to provide an integrated care solution to assist patients, their families and their providers in managing the full range of health issues that kidney patients face on a daily basis.

11 Sep 2009

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

10 Sep 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).

10 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009

Drought, food shortages lead Guatemala to declare 'state of public calamity'

"Guatemalan President Alvaro Colom declared 'a state of public calamity' late Tuesday to help mobilize funds and resources to confront a food shortage that will affect thousands of families," the Associated Press reports (9/9).

10 Sep 2009

Retail clinics offer more treatments for chronic diseases

Retail health clinics are reevaluating their offerings. The Wall Street Journal reports: "Retail health clinics are adding treatments for chronic diseases such as asthma to their repertoire, hoping to find steadier revenue, but putting the clinics into greater competition with doctors' groups and hospitals."

10 Sep 2009

U.S. public health officials recommend early flu vaccination

With increased influenza activity anticipated this fall, U.S. public health officials and other leading medical experts today urged Americans to be vigilant and get immunized early for protection against seasonal influenza - a threat to Americans' health each and every year.

10 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

FDA removes clinical hold on HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.

10 Sep 2009

NHSA and Together Rx Access collaborate to improve prescription access

The National Head Start Association (NHSA) and Together Rx Access announced today a collaboration to launch the Together Rx Access(R) FOR HEAD START Card to help eligible uninsured individuals and families associated with Head Start access immediate and meaningful savings on prescription medicines and products right at their neighborhood pharmacies.

10 Sep 2009

Acorda Therapeutics announces Phase 3 Fampridine-SR trial findings

Data from a long-term open-label extension study from the first Phase 3 Fampridine-SR trial, known as MS-F203, showed that 24.9% of extension study participants with multiple sclerosis (MS) met the criteria as Extension Timed Walk Responders (ETWRs) after one year of treatment and demonstrated improved walking speed over a two year period.

10 Sep 2009

High cost of health care not justified

A policy paper that identifies and analyzes the key drivers of health care costs was released today by the American College of Physicians (ACP). Controlling Health Care Costs While Promoting the Best Possible Health Outcomes provides nearly four dozen recommendations to achieve better quality care to more people.

10 Sep 2009

Lock-Tight Facet Fixation System used performing posterior spinal fixation procedures

Spine surgeon David Raskas, M.D. at the Frontenac Surgery and Spine care Center has been performing outpatient, minimally invasive, posterior spinal fixation procedures on patients using the Lock-Tight Facet Fixation System, a unique technology that enables surgeons to fixate the facet joint without needing to perform an open procedure that usually requires fastening and fixating with pedicle screws and rods.

10 Sep 2009

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Affymax, Inc. today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009.

10 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

WHO's Chan says swine flu will 'test' world on 'fairness'

Addressing a meeting of South East Asian health ministers Tuesday, WHO Director-General Margaret Chan said the H1N1 (swine) flu pandemic will "test the world on the issue of fairness" and "reveal in a measurable and tragic way the consequences of decades of failure to invest adequately in basic health systems and infrastructure,"

10 Sep 2009